{"id":82468,"date":"2025-10-20T10:37:04","date_gmt":"2025-10-20T10:37:04","guid":{"rendered":"https:\/\/www.cofb.org\/?p=82468"},"modified":"2025-10-23T10:37:37","modified_gmt":"2025-10-23T10:37:37","slug":"quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/es\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/","title":{"rendered":"\u00bfCu\u00e1les son las nuevas estrategias en c\u00e1ncer de pr\u00f3stata y vejiga?"},"content":{"rendered":"

El pasado 8 de octubre, el Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB)<\/strong> acogi\u00f3 la jornada formativa \u201cNuevas estrategias en c\u00e1ncer de pr\u00f3stata y vejiga: presente y futuro<\/strong>\u201d, con la colaboraci\u00f3n de la Sociedad Catalana de Farmacia Cl\u00ednica<\/strong> (SCFC) y el patrocinio de Johnson&Johnson<\/a>. La sesi\u00f3n cont\u00f3 con la participaci\u00f3n de Natalia Picola<\/strong>, ur\u00f3loga adjunta al Servicio de Urolog\u00eda del Hospital Universitario de Bellvitge y miembro del equipo m\u00e9dico de Urocl\u00ednica; Georgia Anguera<\/strong>, onc\u00f3loga m\u00e9dica especialista en genitourinario, adjunta al Servicio de Oncolog\u00eda M\u00e9dica del Hospital de la Santa Cruz y San Pablo; In\u00e9s Monge<\/strong>, farmac\u00e9utica del Servicio de Farmacia del Hospital Cl\u00ednic de Barcelona; y Enric Lizano<\/strong>, farmac\u00e9utico y t\u00e9cnico de la Divisi\u00f3n de uso racional del medicamento del \u00c1rea del Medicamento del Servicio Catal\u00e1n de la Salud. David Conde<\/strong>, vocal de Hospitales del COFB, moder\u00f3 la sesi\u00f3n.<\/p>\n\n\n\n

Los objetivos de la formaci\u00f3n<\/strong>, dirigida a farmac\u00e9uticos\/cas de hospital y de atenci\u00f3n primaria, fueron revisar la fisiopatolog\u00eda y las dianas terap\u00e9uticas<\/strong> del c\u00e1ncer de pr\u00f3stata y de vejiga<\/strong>, actualizar la gesti\u00f3n y el tratamiento<\/strong> del c\u00e1ncer de pr\u00f3stata, conocer aspectos de atenci\u00f3n farmac\u00e9utica<\/strong> relacionados con la dispensaci\u00f3n y el seguimiento<\/strong> y reflexionar sobre los mecanismos para la incorporaci\u00f3n de la innovaci\u00f3n<\/strong> en el sistema sanitario<\/strong>.<\/p>\n\n\n\n

Durante la presentaci\u00f3n, David Conde<\/strong> explic\u00f3 la necesidad de \u201chacer un repaso general de la patolog\u00eda<\/strong> y tener unas pinceladas de lo que vendr\u00e1 a futuro. La innovaci\u00f3n llega muy r\u00e1pidamente en estos c\u00e1nceres y debe llegar al paciente, ya que se est\u00e1 consiguiendo cambiar la evoluci\u00f3n de la enfermedad<\/strong>". Adem\u00e1s, a\u00f1adi\u00f3 que la participaci\u00f3n de la farmacia en este escenario "tambi\u00e9n es importante, porque se puede conseguir no s\u00f3lo uno impacto por el paciente<\/strong>, sino que tambi\u00e9n por la econom\u00eda<\/strong>\u201d.<\/p>\n\n\n\n

Alcance del c\u00e1ncer de pr\u00f3stata en la poblaci\u00f3n masculina<\/h2>\n\n\n\n

En la primera presentaci\u00f3n, Natalia Picola<\/strong> la arranc\u00f3 recordando que el c\u00e1ncer de pr\u00f3stata<\/strong> \u201ces la segunda neoplasia m\u00e1s diagnosticada en el hombre<\/strong> a nivel mundial y la primera a partir de los 55 a\u00f1os. A lo largo de 2020 se detectaron 1,4 millones de nuevos diagn\u00f3sticos<\/strong> a escala mundial y, en Espa\u00f1a, es la tercera causa de muerte por c\u00e1ncer entre los hombres\u201d.<\/p>\n\n\n\n

\"Natalia<\/a>
Natalia Picola, en un momento de su presentaci\u00f3n.<\/figcaption><\/figure>\n\n\n\n

Frente a esta situaci\u00f3n, Picola afirm\u00f3 que la mayor\u00eda de los pacientes<\/strong> que sufren esta enfermedad \u201cson diagnosticados en fases iniciales<\/strong> y con el c\u00e1ncer muy localizado<\/strong>. Existen numerosos programas de detecci\u00f3n individual precoz, y uno de los grandes cambios<\/strong> en este sentido que ya se est\u00e1 consolidando es la imagen molecular<\/strong>\u201d.<\/p>\n\n\n\n

Impacto del carcinoma uroterial en Espa\u00f1a<\/h2>\n\n\n\n

Georgia Anguera<\/strong> inici\u00f3 su exposici\u00f3n teniendo muy presente el impacto del carcinoma urotelial<\/strong> en Espa\u00f1a: \u201cSe trata del quinto c\u00e1ncer m\u00e1s diagnosticado<\/strong> en el pa\u00eds durante el 2025. Entre los factores de riesgo<\/strong> est\u00e1 el tabaco, la exposici\u00f3n a t\u00f3xicos laborales<\/strong> como las aminas arom\u00e1ticas<\/strong> y la esquistosomiasis<\/strong>\u201d.<\/p>\n\n\n\n

En cuanto a la presentaci\u00f3n cl\u00ednica de la tipolog\u00eda<\/strong> m\u00e1s com\u00fan en el c\u00e1ncer de vejiga, \u201cen el 80% de los casos los pacientes sufren hematuria<\/strong> y s\u00edntomas urinarios irritativos<\/strong> como la disuria\u201d.<\/p>\n\n\n\n

\"Georgia<\/a>
Georgia Anguera explic\u00f3 los avances significativos en los \u00faltimos a\u00f1os ligados al carcinoma urotelial.<\/figcaption><\/figure>\n\n\n\n

Anguera finaliz\u00f3 su ponencia afirmando que existe avances cient\u00edficos significativos<\/strong> en los \u00faltimos a\u00f1os ligados al carcinoma urotelial: \u201cEn cuanto a la enfermedad localizada<\/strong>, el tratamiento actual es quimioterapia<\/strong> basada en cisplatino<\/strong>, cistectom\u00eda<\/strong> y Nivolumab<\/strong>, mientras que en carcinoma metast\u00e1tico<\/strong>, existe la quimioterapia basada en platino <\/strong>y la reciente aprobaci\u00f3n de Erdafitinib<\/strong>, la primera droga con diana terap\u00e9utica en carcinoma urotelial\u201d.<\/p>\n\n\n\n

Estrategias terap\u00e9uticas en c\u00e1ncer de pr\u00f3stata y vejiga<\/h2>\n\n\n\n

\u201cEl arsenal terap\u00e9utico disponible<\/strong> en c\u00e1ncer de pr\u00f3stata<\/strong> es m\u00e1s amplio que en el c\u00e1ncer de vejiga<\/strong>", afirm\u00f3 In\u00e9s Monge durante la tercera parte de la conferencia. En este contexto, la elecci\u00f3n del tratamiento en el caso de la pr\u00f3stata debe tomarse "teniendo en cuenta el perfil de seguridad del f\u00e1rmaco<\/strong> y las condiciones cl\u00ednicas del paciente<\/strong>, incluyendo comorbilidades y polifarmacia asociada<\/strong>\u201d.<\/p>\n\n\n\n

\"Els<\/a>
Los tratamientos relacionados con el c\u00e1ncer de vejiga fueron descritos por In\u00e9s Monge.<\/figcaption><\/figure>\n\n\n\n

En cuanto a los tratamientos relacionados con el c\u00e1ncer de vejiga<\/strong>, \u201cen caso de que no se localice en un m\u00fasculo-invasivo<\/strong>, se llevar\u00e1 a cabo un tratamiento intravesical. Si se encuentra en un m\u00fasculo invasivo, debe realizarse quimioterapia<\/strong>, cistectom\u00eda radical<\/strong> o inmunoterapia<\/strong>". Finalmente, si hay met\u00e1stasis, "se llevar\u00e1 a cabo quimioterapia, inmunoterapia o terapias dirigidas".<\/p>\n\n\n\n

En el \u00e1mbito estrategias terap\u00e9uticas ligadas a este c\u00e1ncer<\/strong>, Monge indic\u00f3 que "hay que dar relevancia a la vigilancia activa, la cirug\u00eda, la radioterapia y la hormonoterapia".<\/p>\n\n\n\n

M\u00e1s ensayos y evidencia cient\u00edfica en el sistema sanitario<\/h2>\n\n\n\n

Con relaci\u00f3n a las tendencias de futuro<\/strong> para la incorporaci\u00f3n de la innovaci\u00f3n en estos dos c\u00e1nceres dentro del sistema sanitario<\/strong>, Enric Lizano <\/strong>afirm\u00f3 que, en Espa\u00f1a, "existe una clara preferencia en externalizar la innovaci\u00f3n. Adem\u00e1s, las peque\u00f1as mol\u00e9culas<\/strong> a\u00fan protagonizan m\u00e1s de la mitad de los acuerdos<\/strong> por su simplicidad y coste, y la oncolog\u00eda sigue liderando el 40% de los acuerdos<\/strong> que se llevan a cabo\u201d.<\/p>\n\n\n\n

\"Les
Las tendencias de futuro para la incorporaci\u00f3n de la innovaci\u00f3n en ambos c\u00e1nceres corri\u00f3 a cargo de Enric Lizano.<\/figcaption><\/figure>\n\n\n\n

A la hora de afrontar los retos actuales y de futuro<\/strong> contra estos dos c\u00e1nceres, \u201ces necesario el desarrollo de nuevos marcos<\/strong>, dise\u00f1ar nuevos ensayos cl\u00ednicos<\/strong> que proporcionen claridad, m\u00e1s coordinaci\u00f3n entre laboratorios<\/strong> y mejorar la gesti\u00f3n y el enfoque en indicaciones espec\u00edficas<\/strong>\u201d.<\/p>\n\n\n\n

Como conclusi\u00f3n final, Lizano defendi\u00f3 que, si se quiere que la innovaci\u00f3n contra estos c\u00e1nceres llegue a Espa\u00f1a, \u201cse han de incrementar las novedades<\/strong> y sumar m\u00e1s evidencia cient\u00edfica<\/strong>, establecer medidas de acceso gestionado como herramientas para reducir la presi\u00f3n<\/strong> y, finalmente, la necesidad de focalizarse en el valor<\/strong>, la eficiencia<\/strong> y los pacientes<\/strong>\u201d.<\/p>\n\n\n\n

Con el patrocinio de:<\/strong><\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

<\/p>","protected":false},"excerpt":{"rendered":"

El pasado 8 de octubre, el Colegio de Farmac\u00e9uticos de Barcelona (COFB) acogi\u00f3 la jornada formativa "Nuevas estrategias en c\u00e1ncer de pr\u00f3stata y vejiga: presente y futuro", con la colaboraci\u00f3n de la Sociedad Catalana de Farmacia Cl\u00ednica (SCFC) y el patrocinio de Johnson&Johnson. La sesi\u00f3n cont\u00f3 con la participaci\u00f3n de Natalia [\u2026]<\/p>","protected":false},"author":10,"featured_media":82489,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[23,57],"tags":[3070,723,975,18,19,69,70,44,724],"class_list":["post-82468","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-destacats","category-mon-collegial","tag-bufeta","tag-cancer","tag-cancer-de-prostata","tag-cofb","tag-collegi-de-farmaceutics-de-barcelona","tag-farmacia-comunitaria","tag-formacio","tag-malaltia","tag-oncologia"],"yoast_head":"\nQuines s\u00f3n les noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta? - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"description\" content=\"El COFB acull la jornada "Noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta: present i futur", amb el patrocini de Johnson&Johnson\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cofb.org\/es\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Quines s\u00f3n les noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta? - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"El COFB acull la jornada "Noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta: present i futur", amb el patrocini de Johnson&Johnson\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cofb.org\/es\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-20T10:37:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-23T10:37:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Xavier Magraner\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Xavier Magraner\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/\"},\"author\":{\"name\":\"Xavier Magraner\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/e46d741cfb92c985a083d163d8270ae4\"},\"headline\":\"Quines s\u00f3n les noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta?\",\"datePublished\":\"2025-10-20T10:37:04+00:00\",\"dateModified\":\"2025-10-23T10:37:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/\"},\"wordCount\":1112,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg\",\"keywords\":[\"bufeta\",\"c\u00e0ncer\",\"c\u00e0ncer de pr\u00f2stata\",\"COFB\",\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"farm\u00e0cia comunit\u00e0ria\",\"Formaci\u00f3\",\"malaltia\",\"oncologia\"],\"articleSection\":[\"Destacats\",\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/\",\"url\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/\",\"name\":\"Quines s\u00f3n les noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta? - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg\",\"datePublished\":\"2025-10-20T10:37:04+00:00\",\"dateModified\":\"2025-10-23T10:37:37+00:00\",\"description\":\"El COFB acull la jornada \\\"Noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta: present i futur\\\", amb el patrocini de Johnson&Johnson\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#primaryimage\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg\",\"width\":2560,\"height\":1440},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Quines s\u00f3n les noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/e46d741cfb92c985a083d163d8270ae4\",\"name\":\"Xavier Magraner\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa0d1d4df59f71f88eebd5796c5388ff41c58d83c5301eb6e1d65646a289c37d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa0d1d4df59f71f88eebd5796c5388ff41c58d83c5301eb6e1d65646a289c37d?s=96&d=mm&r=g\",\"caption\":\"Xavier Magraner\"},\"url\":\"https:\/\/www.cofb.org\/es\/author\/xmagraner\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Quines s\u00f3n les noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"El COFB acull la jornada \"Noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta: present i futur\", amb el patrocini de Johnson&Johnson","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cofb.org\/es\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/","og_locale":"es_ES","og_type":"article","og_title":"Quines s\u00f3n les noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"El COFB acull la jornada \"Noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta: present i futur\", amb el patrocini de Johnson&Johnson","og_url":"https:\/\/www.cofb.org\/es\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2025-10-20T10:37:04+00:00","article_modified_time":"2025-10-23T10:37:37+00:00","og_image":[{"width":2560,"height":1440,"url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg","type":"image\/jpeg"}],"author":"Xavier Magraner","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrito por":"Xavier Magraner","Tiempo de lectura":"7 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#article","isPartOf":{"@id":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/"},"author":{"name":"Xavier Magraner","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/e46d741cfb92c985a083d163d8270ae4"},"headline":"Quines s\u00f3n les noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta?","datePublished":"2025-10-20T10:37:04+00:00","dateModified":"2025-10-23T10:37:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/"},"wordCount":1112,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg","keywords":["bufeta","c\u00e0ncer","c\u00e0ncer de pr\u00f2stata","COFB","Col\u00b7legi de Farmac\u00e8utics de Barcelona","farm\u00e0cia comunit\u00e0ria","Formaci\u00f3","malaltia","oncologia"],"articleSection":["Destacats","M\u00f3n col\u00b7legial"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/","url":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/","name":"Quines s\u00f3n les noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#primaryimage"},"image":{"@id":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg","datePublished":"2025-10-20T10:37:04+00:00","dateModified":"2025-10-23T10:37:37+00:00","description":"El COFB acull la jornada \"Noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta: present i futur\", amb el patrocini de Johnson&Johnson","breadcrumb":{"@id":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#primaryimage","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg","width":2560,"height":1440},{"@type":"BreadcrumbList","@id":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Quines s\u00f3n les noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta?"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/e46d741cfb92c985a083d163d8270ae4","name":"Xavier Magraner","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa0d1d4df59f71f88eebd5796c5388ff41c58d83c5301eb6e1d65646a289c37d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa0d1d4df59f71f88eebd5796c5388ff41c58d83c5301eb6e1d65646a289c37d?s=96&d=mm&r=g","caption":"Xavier Magraner"},"url":"https:\/\/www.cofb.org\/es\/author\/xmagraner\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg",2560,1440,false],"thumbnail":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-150x150.jpg",150,150,true],"medium":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-300x169.jpg",300,169,true],"medium_large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-768x432.jpg",768,432,true],"large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-1024x576.jpg",1024,576,true],"1536x1536":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-1536x864.jpg",1536,864,true],"2048x2048":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-2048x1152.jpg",2048,1152,true],"trp-custom-language-flag":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-18x10.jpg",18,10,true]},"uagb_author_info":{"display_name":"Xavier Magraner","author_link":"https:\/\/www.cofb.org\/es\/author\/xmagraner\/"},"uagb_comment_info":0,"uagb_excerpt":"El passat 8 d\u2019octubre, el Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) va acollir la jornada formativa \u201cNoves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta: present i futur\u201d, amb la col\u00b7laboraci\u00f3 de la Societat Catalana de Farm\u00e0cia Cl\u00ednica (SCFC) i el patrocini de Johnson&Johnson. La sessi\u00f3 va comptar amb la participaci\u00f3 de Natalia […]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/82468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/comments?post=82468"}],"version-history":[{"count":14,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/82468\/revisions"}],"predecessor-version":[{"id":82573,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/82468\/revisions\/82573"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media\/82489"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media?parent=82468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/categories?post=82468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/tags?post=82468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}